IBRN - ETF AI Analysis
Top Page
iShares Neuroscience and Healthcare ETF (IBRN)
Rating:56Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year, supported by solid returns over the past few months.
Top Holdings Showing Strong Momentum
Several of the largest positions, such as Xenon, Dianthus Therapeutics, and Alkermes, have posted strong year-to-date gains, helping drive the fund’s results.
Global Exposure Within a Focused Theme
While the fund is mainly invested in U.S. companies, it also includes holdings from countries like South Korea, Sweden, and Switzerland, adding some international diversification within the neuroscience and healthcare theme.
Negative Factors
High Sector Concentration in Health Care
With the vast majority of assets in the health care sector, the ETF is heavily exposed to industry-specific risks such as regulatory changes and drug approval setbacks.
Limited Diversification Across Sectors and Countries
The fund’s strong tilt toward U.S. health care stocks means it offers little protection if this sector or region faces a downturn.
Moderately High Expense Ratio
The ETF’s expense ratio is on the higher side for a passive fund, which can modestly reduce net returns over time compared with lower-cost alternatives.
IBRN vs. SPDR S&P 500 ETF (SPY)
AUM5.63M
RegionGlobal
Expense Ratio0.47%
Beta1.12
IssueriShares
Inception DateAug 24, 2022
Dividend Yield0.85%
Asset ClassEquity
Index TrackedNYSE FactSet Global Neuro Biopharma and MedTech Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,277
30 Day Avg. Volume2,570
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
53.19Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering66
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IBRN Summary
The iShares Neuroscience and Healthcare ETF (IBRN) tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index, focusing on health care companies working on brain-related drugs, treatments, and medical technology. It mainly holds U.S. biotech and pharma firms, including well-known names like Biogen and Neurocrine, along with other specialized drug developers. Someone might invest in IBRN if they want growth potential from cutting-edge medical research and to bet on rising demand for new neurological therapies. However, this fund is heavily concentrated in health care and biotech, so its price can swing a lot and may rise or fall sharply with news about drug trials and approvals.
How much will it cost me?The iShares Neuroscience and Healthcare ETF (IBRN) has an expense ratio of 0.47%, which means you’ll pay $4.70 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires more active management to target specific companies in the neuroscience and healthcare fields.
What would affect this ETF?The iShares Neuroscience and Healthcare ETF (IBRN) could benefit from growing global demand for advanced neurological treatments and breakthroughs in biotechnology, as well as increased funding for health care innovation. However, it may face challenges from regulatory hurdles in drug approvals, potential economic slowdowns impacting research budgets, and competition within the pharmaceutical and biotech sectors. Its global exposure and focus on cutting-edge companies provide opportunities but also expose it to risks tied to international market conditions.
IBRN Top 10 Holdings
IBRN is a pure play on neuroscience and biotech, and its story is being written by a handful of high‑octane drug developers. Alkermes is the clear bright spot, rising on strong profits and savvy dealmaking, while Arrowhead, Axsome, and Dianthus add more fuel with upbeat trial news and solid momentum. On the flip side, Praxis has been lagging, quietly acting as a brake on returns, and ACADIA has been more mixed. With nearly all exposure in global health care names, this fund lives and dies by the fortunes of a concentrated group of innovative biopharma stocks.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Dianthus Therapeutics | 5.10% | $289.57K | $5.62B | 364.98% | 61 Neutral | |
| Xenon | 5.01% | $284.58K | $6.40B | 112.18% | 48 Neutral | |
| Praxis Precision Medicines | 4.86% | $275.91K | $8.70B | 446.68% | 58 Neutral | |
| Alkermes | 4.79% | $272.34K | $8.76B | 93.38% | 80 Outperform | |
| Scholar Rock Holding | 4.46% | $253.33K | $5.79B | 21.63% | 50 Neutral | |
| ACADIA Pharmaceuticals | 4.45% | $253.00K | $4.27B | 7.72% | 75 Outperform | |
| PTC Therapeutics | 4.30% | $244.06K | $6.50B | 66.52% | 72 Outperform | |
| Neurocrine | 4.24% | $240.82K | $17.36B | 29.20% | 80 Outperform | |
| Biogen | 4.04% | $229.37K | $29.19B | 51.31% | 74 Outperform | |
| Axsome Therapeutics | 3.96% | $224.87K | $12.33B | 125.29% | 57 Neutral |
IBRN Technical Analysis
Positive
―
Price Trends
36.42
Positive
34.81
Positive
32.86
Positive
Market Momentum
0.32
Positive
51.67
Neutral
32.96
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBRN, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 38.41, equal to the 50-day MA of 36.42, and equal to the 200-day MA of 32.86, indicating a neutral trend. The MACD of 0.32 indicates Positive momentum. The RSI at 51.67 is Neutral, neither overbought nor oversold. The STOCH value of 32.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBRN.
IBRN Peer Comparison
Comparison Results
Performance Comparison
IBRN
iShares Neuroscience and Healthcare ETF
37.77
14.67
63.51%
HTEC
ROBO Global Healthcare Technology and Innovation ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents